Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms
Clinical and Hematologic Risk Factors of Right Ventricular Dysfunction and Pulmonary Hypertension in Myeloproliferative Neoplasms
This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.
研究概览
详细说明
Myeloproliferative neoplasms (MPNs) are associated with an increased risk of pulmonary hypertension and right ventricular dysfunction. This observational study will include adults with confirmed polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
All participants will undergo clinical assessment, laboratory evaluation, and echocardiography to assess pulmonary artery systolic pressure and right ventricular systolic function (TAPSE, FAC, and tissue Doppler S').
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Esraa M Ahmed, Resident
- 电话号码：+20 10 99071931
- 邮箱：esraamedhat449@gmail.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult patients with confirmed myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) attending the Hematology Unit and Critical Care Department at Assiut University Hospital.
描述
Inclusion Criteria:
- - Age 18 years or older
- Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)
- Stable clinical condition
- Written informed consent
Exclusion Criteria:
- - Significant left-sided valvular heart disease
- Congenital heart disease
- COPD or interstitial lung disease causing pulmonary hypertension
- Poor echocardiographic window
学习计划
研究是如何设计的？
设计细节
- 观测模型：CASE_ONLY
- 时间观点：CROSS_SECTIONAL
队列和干预
团体/队列 |
|---|
|
Single cohort: Patients with myeloproliferative neoplasms
Adult patients with myeloproliferative neoplasms who will undergo clinical, laboratory, and echocardiographic assessment for pulmonary hypertension and right ventricular dysfunction. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prevalence of Pulmonary Hypertension in MPN Patients
大体时间：Baseline
|
PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated. |
Baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prevalence of right ventricular dysfunction
大体时间：Baseline
|
Proportion of patients with right ventricular dysfunction defined by TAPSE <17 mm, RV fractional area change <35%, or tissue Doppler S' <9.5 cm/s |
Baseline
|
|
Pulmonary artery systolic pressure
大体时间：Baseline
|
Mean estimated pulmonary artery systolic pressure (mmHg) measured by echocardiography |
Baseline
|
|
Tricuspid annular plane systolic excursion (TAPSE)
大体时间：Baseline
|
Mean TAPSE value (mm) measured by echocardiography. |
Baseline
|
|
Right ventricular fractional area change
大体时间：Baseline
|
Mean right ventricular fractional area change (%) measured by echocardiography. |
Baseline
|
合作者和调查者
调查人员
- 学习椅：Refaat f abdel all, prof、Critical care unit Internal Medicine Department, Assiut University Hospitals
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.